Research and Markets


Printer Friendly

Printed from http://www.researchandmarkets.com/reports/314805


Cardiovascular Market Drugs and Devices Market: Successes and Cardiovascular Setbacks in the Third Quarter of 2005


Description: The third quarter of 2005 was a period of conspicuous change for the cardiovascular market. Several significant events affected drugs and devices on the market and in the pipeline.

By examining the most noteworthy of these events in this report, our cardiology team provide a snapshot of important forces driving the cardiovascular market and an analysis of the implications of those forces. We begin by looking at events in the cardiac stent market; several third-quarter events played a key role in shaping this field. We then discuss successes and setbacks for specific agents as they gained regulatory approvals or faced challenges owing to the emergence of study findings or potential generics competition.


Business Implications

- Several significant events affected cardiovascular drugs and devices on the market and in the pipeline during the third quarter of 2005. Events in the cardiac stent market during the quarter played a key role in shaping the competition in this field. In addition, several drugs gained regulatory approval or faced challenges owing to the emergence of study findings or potential generics competition.

- Head-to-head trials published in the third quarter of 2005 generally favored the Cypher drug-eluting stent from Cordis/Johnson & Johnson over Boston Scientific's Taxus Express2 stent. Such studies, together with issues concerning Taxus's quality control and a $598 million expense for a legal settlement, led to persistent woes for Boston Scientific in the quarter. Other important events included Medtronic's launch of the Endeavor stent and the European Commission's approval of J&J's acquisition of medical device maker Guidant.

- Several important approvals of new drugs as well as new indicationsfor already marketed drugs occurred during the third quarter of 2005. The approval of Pfizer's Revatio (sildenafil) and Servier's Procoralan (ivabradine) is likely to have the largest impact on the cardiovascular market.

- Currently marketed drugs that have found success in the cardiovascular market in the past confronted new challenges. Scios's Natrecor (nesiritide) saw its sales drop amid controversy about its widespread, off-label use in the United States in outpatients. Sanofi-Aventis's Lovenox (enoxaparin) will likely face generics competition following patent challenges.


Contents: Introduction
Competition Intensifies in Cardiac Stent Market
Approvals of New Drugs/Indications Expand Treatment Options
Current Drugs Face Challenges to Initial Market Success

List of Figures and Tables

Figure 1. Select Milestones in the Drug-Eluting Stent Market
Figure 2. Sales Comparison: Boston Scientific’s Taxus Stent vs. Cordis/Johnson & Johnson’s Cypher Stent (millions of U.S. dollars)
Table 1. Important Approvals/Submissions for New Drugs and for New Indications for Marketed Drugs, Third-Quarter 2005
Table 2. Worldwide Sales of Leading Statins, 2004


Companies Mentioned Companies mentioned in this report include: - AstraZeneca - Boston Scientific - Bristol-Myers Squibb - Cordis - CV Therapeutics - Encysive Pharmaceuticals - Guidant - Johnson & Johnson - Medinol - Medtronic - Merck & CO. - NitroMed - Novartis - Pfizer - Servier - Solvay Pharmaceuticals - Wyeth


Ordering: Order Online - visit http://www.researchandmarkets.com/reports/314805

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


Research and Markets Page 1 of 2
Printed 12/10/2008 03:39:02
Fax Order Form

To place an order via fax simply print this form, fill in the information below and fax the completed form to the number at the bottom of this page. If you have any questions please email help@researchandmarkets.com


Order information

Please verify that the product information is correct and select the format you require.

Product Name:
Cardiovascular Market Drugs and Devices Market: Successes and Cardiovascular Setbacks in the Third Quarter of 2005
Web Address:
http://www.researchandmarkets.com/reports/314805
Office Code:
OCHKFHONSQY

Report formats

Please enter the quantity of the report format you require.

Format Quantity Price
Electronic (PDF) - Single User €749.00




Contact information

Please enter all the information below in BLOCK CAPITALS.

First Name:   Last Name:  
Email Address:
Job Title:
Organisation:
Address:
City:
Postal/Zip Code:
Country:
Phone Number:
Fax Number:


Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353 1 481 1716 or +353 1 653 1571 - From Rest of World

Research and Markets Page 2 of 2
Printed 12/10/2008 03:39:02

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

 Pay by Credit Card:
American Express
Diners Club
Master Card
Visa
Cardholder Name:
Expiry Date: /
Card Number:
CVV Security Code:
Issue Date: /   (Diners Club only)


 Pay by Check:
Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


 Pay by Wire Transfer:
Please transfer funds to:

Account number: 83313083
Sort code: 98-53-30
Swift code: ULSBIE2D
IBAN number: IE78ULSB98533083313083
Bank Address: Ulster Bank,
27-35 Main St,
Blackrock,
Co. Dublin,
Ireland.


If you have a Marketing Code please enter it below:

Marketing Code:


Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp



Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353 1 481 1716 or +353 1 653 1571 - From Rest of World